Details

Autor(en) / Beteiligte

• FISCHER, Kirsten
• CRAMER, Paula
• TRESCKOW, Julia Von
• FINK, Anna-Maria
• BÜHLER, Andreas
• WINKLER, Dirk
• KREUZER, Karl-Anton
• STAIB, Peter
• RITGEN, Matthias
• KNEBA, Michael
• DÖHNER, Hartmut
• EICHHORST, Barbara F
• BUSCH, Raymonde
• HALLEK, Michael
• STILGENBAUER, Stephan
• WENDTNER, Clemens-Martin
• BÖTTCHER, Sebastian
• BAHLO, Jasmin
• SCHUBERT, Jöerg
• PFLÜGER, Karl H
• SCHOTT, Silke
• GOEDE, Valentin
• ISFORT, Susanne

Titel

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Ist Teil von

• Journal of clinical oncology, 2012-09, Vol.30 (26), p.3209-3216

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2012

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL). In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. Bendamustine was administered at a dose of 90 mg/m(2) on days 1 and 2 combined with 375 mg/m(2) rituximab on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses. Overall response rate was 88.0% (95% CI, 80.7% to 100.0%) with a complete response rate of 23.1% and a partial response rate of 64.9%. Ninety percent of patients with del(11q), 94.7% with trisomy 12, 37.5% with del(17p), and 89.4% with unmutated IGHV status responded to treatment. After a median observation time of 27.0 months, median event-free survival was 33.9 months, and 90.5% of patients were alive. Grade 3 or 4 severe infections occurred in 7.7% of patients. Grade 3 or 4 adverse events for neutropenia, thrombocytopenia, and anemia were documented in 19.7%, 22.2%, and 19.7% of patients, respectively. Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL.